WallStSmart

Ethos Technologies Inc. Class A Common Stock (LIFE) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target

Ethos Technologies Inc. Class A Common Stock stock (LIFE) is currently trading at $10.09. Ethos Technologies Inc. Class A Common Stock PE ratio is 8.64. Ethos Technologies Inc. Class A Common Stock PS ratio (Price-to-Sales) is 1.60. Analyst consensus price target for LIFE is $20.25. WallStSmart rates LIFE as Moderate Buy.

  • LIFE PE ratio analysis and historical PE chart
  • LIFE PS ratio (Price-to-Sales) history and trend
  • LIFE intrinsic value — DCF, Graham Number, EPV models
  • LIFE stock price prediction 2025 2026 2027 2028 2029 2030
  • LIFE fair value vs current price
  • LIFE insider transactions and insider buying
  • Is LIFE undervalued or overvalued?
  • Ethos Technologies Inc. Class A Common Stock financial analysis — revenue, earnings, cash flow
  • LIFE Piotroski F-Score and Altman Z-Score
  • LIFE analyst price target and Smart Rating
LIFE

Ethos Technologies Inc.

NASDAQFINANCIAL SERVICES
$10.09
$0.04 (-0.39%)
52W$9.45
$19.00
Target$20.25+100.7%

📊 No data available

Try selecting a different time range

IV

LIFE Intrinsic Value Analysis for Value Investors

Benjamin Graham Formula · Ethos Technologies Inc. Class A Common Stock (LIFE)

Margin of Safety
+80.7%
Strong Buy Zone
LIFE Fair Value
$53.35
Graham Formula
Current Price
$10.09
$43.26 below fair value
Undervalued
Fair: $53.35
Overvalued
Price $10.09
Graham IV $53.35
Analyst $20.25

LIFE trades at a significant discount to its Graham intrinsic value of $53.35, offering a 81% margin of safety — a level value investors typically seek before buying.

Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.

WallStSmart

Smart Analysis

Ethos Technologies Inc. Class A Common Stock (LIFE) · 8 metrics scored

Smart Score

63
out of 100
Grade: C+
Buy
Investment Rating

Category Performance

WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.

Investment Thesis

Strong fundamentals in return on equity, operating margin, price/sales. Fundamentals are solid but monitor weak areas for improvement.

Ethos Technologies Inc. Class A Common Stock (LIFE) Key Strengths (6)

Avg Score: 8.8/10
Revenue GrowthGrowth
65.50%10/10

Revenue surging 65.50% year-over-year

EPS GrowthGrowth
161.60%10/10

Earnings per share surging 161.60% year-over-year

Return on EquityProfitability
21.00%9/10

Every $100 of equity generates $21 in profit

Operating MarginProfitability
22.20%8/10

Strong operational efficiency: $22 kept per $100 revenue

Price/SalesValuation
1.608/10

Paying $1.60 for every $1 of annual revenue

Profit MarginProfitability
18.40%8/10

Strong profitability: $18 kept per $100 revenue

Supporting Valuation Data

P/E Ratio
8.64
Undervalued
Trailing P/E
8.64
Undervalued
Price/Sales (TTM)
1.596
Undervalued
EV/Revenue
1.277
Undervalued
LIFE Target Price
$20.25
67% Upside

Ethos Technologies Inc. Class A Common Stock (LIFE) Areas to Watch (2)

Avg Score: 5.5/10
Market CapQuality
$619M5/10

Small-cap company with higher risk but more growth potential

Institutional Own.Quality
42.02%6/10

Moderate institutional interest at 42.02%

Ethos Technologies Inc. Class A Common Stock (LIFE) Detailed Analysis Report

Overall Assessment

This company scores 63/100 in our Smart Analysis, earning a C+ grade. Out of 8 metrics analyzed, 6 register as strengths (avg 8.8/10) while 2 fall into concern territory (avg 5.5/10). The category breakdown reveals uneven performance, with some areas requiring attention.

The Bull Case

The strongest argument centers on Revenue Growth, EPS Growth, Return on Equity. Valuation metrics including Price/Sales (1.60) suggest the stock is attractively priced. Profitability is solid with Return on Equity at 21.00%, Operating Margin at 22.20%, Profit Margin at 18.40%. Growth metrics are encouraging with Revenue Growth at 65.50%, EPS Growth at 161.60%.

The Bear Case

The primary concerns are Market Cap, Institutional Own..

Key Dynamics to Monitor

Three factors to monitor going forward. First, whether Market Cap improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 21.00% currently healthy but needing to be sustained. Third, growth sustainability, with Revenue Growth at 65.50% strong but requiring continuation.

Risk Considerations

Based on the metric profile, this is a moderate-to-high risk investment. The weight of evidence leans positive, with more strengths than concerns. Investors should size positions according to their risk tolerance and maintain diversification.

Bottom Line

Mixed fundamentals with both positives (Revenue Growth, EPS Growth) and negatives (Market Cap, Institutional Own.). A cautious approach is warranted. Monitor for improvement in weak areas before increasing conviction.

Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.

LIFE Price-to-Sales(PS) Ratio Chart

Historical valuation based on market cap ÷ trailing 12-month revenue

LIFE's Price-to-Sales ratio of 1.60x trades 19% below its historical average of 1.96x (0th percentile). The current valuation is 29% below its historical high of 2.25x set in Mar 2026, and 0% above its historical low of 1.6x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~2.3x as trailing revenue scaled faster than the stock price.

Compare LIFE with Competitors

Top INSURANCE BROKERS stocks by market cap

Compare any two stocks →

WallStSmart Analysis Synopsis

Data-driven financial summary for Ethos Technologies Inc. Class A Common Stock (LIFE) · FINANCIAL SERVICESINSURANCE BROKERS

The Big Picture

Ethos Technologies Inc. Class A Common Stock is a strong growth company balancing expansion with improving profitability. Revenue reached 388M with 66% growth year-over-year. Profit margins of 18.4% are healthy, with room for further expansion as the business scales.

Key Findings

Strong Revenue Growth

Revenue growing at 66% YoY, reaching 388M. This pace significantly outperforms most INSURANCE BROKERS peers.

Excellent Capital Efficiency

ROE of 2100.0% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.

What to Watch Next

Growth sustainability: can Ethos Technologies Inc. Class A Common Stock maintain 66%+ revenue growth, or will competition slow it down?

Sector dynamics: monitor INSURANCE BROKERS industry trends, competitive moves, and regulatory changes that could impact Ethos Technologies Inc. Class A Common Stock.

Bottom Line

Ethos Technologies Inc. Class A Common Stock offers an attractive blend of growth (66% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.

This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.

Insider Transactions

Loading insider activity...

About Ethos Technologies Inc. Class A Common Stock(LIFE)

Exchange

NASDAQ

Sector

FINANCIAL SERVICES

Industry

INSURANCE BROKERS

Country

USA

aTyr Pharma, Inc., a clinical-stage biotherapeutics company, is dedicated to the discovery and development of drugs based on new immune pathways in the United States. The company is headquartered in San Diego, California.